Abstract
Introduction: This article aimed to investigate the value of D-dimer (DD) and prothrombin fragment 1+2 (PF1+2) in evaluating the risk of venous thromboembolism (VTE) in advanced cancer patients and the effect of preventive anticoagulant therapy.
Method and Material: 137 advanced cancer patients who were hospitalized in The 908th Hospital of Chinese People’s Liberation Army Joint Logistic Support Force Hospital from February 2023 to June 2024 were recruited. They were divided into VTE group (n=49) and non-VTE group (n=88) according to whether VTE occurred. Blood routine test was performed on admission, and the relationship between DD and PF1+2 and VTE was analyzed. The role of DD and PF1+2 as risk assessment indicators for VTE was evaluated. The subjects without VTE were divided into preventive anticoagulant treatment group (AG, n=48) and conventional anticoagulant treatment group (RT, n=40) according to their will. The probability of VTE in the two groups after treatment was counted to verify the effect of preventive anticoagulant intervention.
Result: Before chemotherapy for advanced cancer, DD was higher in the subjects with VTE as against subjects without VTE. DD and PF1+2 after chemotherapy are independent risk factors for VTE. The effect of VTET was different, while other treatments had no distinction. The incidence of VTE in RT group was higher as against AG group, the distinction had statistical meaning. Conclusion: DD and PF1+2 can be used as indicators to evaluate the risk of VTE in advanced
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.